0000914475-24-000075.txt : 20240215 0000914475-24-000075.hdr.sgml : 20240215 20240215174820 ACCESSION NUMBER: 0000914475-24-000075 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Onyia Jude CENTRAL INDEX KEY: 0001894425 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24645074 MAIL ADDRESS: STREET 1: C/O NEUROCRINE BIOSCIENCES, INC. STREET 2: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1708037291.xml FORM 4 X0508 4 2024-02-13 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001894425 Onyia Jude 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Scientific Officer 1 Common Stock 2024-02-13 4 S 0 1432 132.9407 D 13128 D Stock Option 133.84 2024-02-13 4 A 0 54069 0 A 2034-02-13 Common Stock 54069 54069 D Restricted Stock Unit 2024-02-13 4 A 0 10760 0 A Common Stock 10760 10760 D Sale of 1,432 shares of common stock issued upon vesting of 2,717 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,285) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $133.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. /s/ Darin Lippoldt, Attorney-in-Fact 2024-02-15